Santhera Pharmaceuticals Holding AG (SANN) – Strategy, SWOT and Corporate Finance Report
- Pages: 56
- Published: June 2023
- Report Code: MLPH82467FSA
Santhera Pharmaceuticals Holding AG (SANN) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company
Key Highlights
Santhera Pharmaceuticals Holding AG (Santhera) develops and markets novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. The company specifically focuses on the area of neuromuscular and ophthalmological conditions. The company’s lead product candidate, Raxone is developed for the treatment of Leber's hereditary optic neuropathy (LHON) and is approved by the European Marketing Authorization. Raxone is investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. The company operates through its subsidiaries in Switzerland, Liechtenstein, Germany, Canada, the UK, Italy, the Netherlands, and the US. Santhera is headquartered in Pratteln, Switzerland.
Scope
• Detailed information on Santhera Pharmaceuticals Holding AG required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Santhera Pharmaceuticals Holding AG in the form of a SWOT analysis
• An in-depth view of the business model of Santhera Pharmaceuticals Holding AG including a breakdown and examination of key business segments
• News about Santhera Pharmaceuticals Holding AG, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
• Gain understanding of Santhera Pharmaceuticals Holding AG and the factors that influence its strategies.• Track strategic initiatives of the company and latest corporate news and actions.
• Assess Santhera Pharmaceuticals Holding AG as a prospective partner, vendor or supplier.
• Support sales activities by understanding your customers' businesses better.
• Stay up to date on Santhera Pharmaceuticals Holding AGs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Triskel Biopharmaceuticals AG
NicOx SA
CARTHAGENETICS SUISSE Sarl
Capricor Therapeutics Inc
Applied Genetic Technologies Corp
Abliva AB
Sarepta Therapeutics Inc
Oncternal Therapeutics
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.